Project Grant K23AG097987
- The National Institute on Aging awarded the University of Arizona $396,241 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a longitudinal, multi-modal study tracking neuroplasticity changes in preclinical and prodromal Alzheimer's disease stages using transcranial magnetic stimulation (TMS) integrated with blood and MRI biomarkers. The study employs TMS to assess non-invasive, repeatable neurophysiological measures of neuroplasticity and correlates these...
- The National Institute on Aging awarded Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) $889,728 on August 18, 2026, under the Aging Research program (CFDA 93.866) to develop circuit-based multi-focal neurostimulation targeting depression and memory in older adults with Alzheimer's dementia. The project combines transcranial direct current stimulation targeting the left prefrontal cortex to address depressive symptoms with transcranial alternating current stimulation...
- The National Institute on Aging awarded the University of California, Los Angeles $623,176 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research on modifiable risk factors for Alzheimer's disease and related dementias among individuals aged 90 and older. The research triangulates evidence across four data sources—the LifeAfter90 Study (1,397 participants, all aged 90), the 90+ Study (1,630 participants, all aged 90), the Health and Retirement Study (3,359...
- The National Institute on Aging awarded the Research Foundation For Mental Hygiene, Inc., operating through its New York State Psychiatric Institute division, $458,622 on March 1, 2026, under the Aging Research program (CFDA 93.866) to identify the impact of focused ultrasound-induced blood-brain barrier opening on brain-wide memory traces in Alzheimer's disease. The award funds research into the neuronal mechanisms of focused ultrasound combined with microbubbles (FUS-BBBO) as a novel...
- The National Institute on Aging awarded the University of Southern California $149,190 on August 6, 2026, under the Aging Research program (CFDA 93.866) to investigate how early-stage Alzheimer's disease disrupts coordinated release dynamics between acetylcholine and norepinephrine in the cortex and how this discoordination impairs cognitive performance. The research characterizes the evolution of coordinated cortical acetylcholine and norepinephrine release activity in vivo in wildtype mice,...
- The National Institute on Aging awarded the University of California Irvine $1.238 million on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate longitudinal relationships between Alzheimer's disease pathophysiology, local sleep expression, and sleep-dependent memory across preclinical disease stages. The project uses multimodal neuroimaging combining polysomnography, high-density electroencephalography, and high-resolution structural magnetic resonance imaging of...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded the University of California, Los Angeles $146,750 under the Aging Research program (CFDA 93.866) on July 1, 2026, to identify molecular-neuropathological signatures in Alzheimer's disease, frontotemporal lobar degeneration, and long COVID. The recipient will employ single-cell spatial multi-omics on postmortem brain tissues to characterize molecular and cellular alterations linked to selective...
- The National Institute on Aging awarded the University of California, Los Angeles $126,063 on August 5, 2026, under the Aging Research program (CFDA 93.866) to determine the atomic structures of amyloid-beta and tau oligomers and to characterize the molecular interaction between amyloid-beta and the TREM2 receptor on microglia. The award is classified as a Project Grant, specifically a K99/R00 award. The research develops a novel oligomer structure determination pipeline incorporating native...
- The National Institute on Aging awarded The Leland Stanford Junior University $423,500 on April 1, 2026, under the Aging Research program (CFDA 93.866) to investigate dynamic brain circuit mechanisms associated with apathy and disinhibition in individuals with Alzheimer's disease and related dementias. The project addresses neuropsychiatric symptoms that affect nearly 80 percent of individuals with dementia, particularly apathy and disinhibition linked to deficits in motivation and cognitive...
- The National Institute on Aging awarded the University of Southern California $359,735 on September 1, 2026, under the Aging Research program (CFDA 93.866) for a Project Grant (R21AG091332) to develop generative artificial intelligence methods for interpretable Alzheimer's disease detection using denoising diffusion probabilistic models applied to neuroimaging. The project addresses the challenge of distinguishing brain changes attributable to Alzheimer's disease from normal age-related...
The National Institute on Aging awarded the University of California, Los Angeles $169,020 on August 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a clinical trial of repetitive transcranial magnetic stimulation (RTMS) targeting the posterior parietal lobe in Alzheimer's disease patients. The project, titled "Protocol for Maintaining and Improving Mental Status in Alzheimer's Disease (PROMIS-AD): A Study of Broad-Coil Parietal Repetitive Transcranial Magnetic Stimulation for Alzheimer's Dementia," aims to establish the principal investigator as an independent researcher at the intersection of neurodegenerative disease, neuromodulation, and clinical trials. The award supports a feasibility and tolerability study of RTMS over the precuneus to explore biological engagement and clinical efficacy in ameliorating Alzheimer's symptoms, particularly episodic memory impairment through enhancement of default mode network function. The investigator will develop expertise in basic and clinical Alzheimer's disease neuroscience, including electroencephalography methods; application of neuromodulation principles to intervention development; clinical trials in vulnerable populations; and academic career development bridging psychiatry and neurology. Performance occurs in Los Angeles, California from August 1, 2026, through May 31, 2031. The assistance type is a Project Grant, classified as a career development award (K23).
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $169.0k | 7/27/26 |